Figure 2
Figure 2. Combined pretreatment with KGF and androgen blockade maximally restores numbers of total TECs and mTEC subsets by day 26 after BMT. (A-F) Lethally irradiated B6 recipients of allogeneic (BALB/c) bone marrow were left untreated (BMT Control) or pretreated with KGF, leuprolide acetate, or KGF + leuprolide acetate and analyzed for absolute numbers of TEC and TEC subsets at day 26 after BMT. Single-cell suspensions were prepared from enzymatic digests of individual thymi and used to determine total thymic epithelial cells (TEC; CD45−MHC-II+) (A), cortical TEC (cTEC; CD45−MHC-II+Ly51+) (B), medullary TEC (mTEC; CD45−MHC-II+Ly51−) (C), UEA-1+ mTEClo (CD45−MHC-IIlowLy51− UEA-1+) (D), UEA-1+ mTEChi (CD45−MHC-IIhighLy51− UEA-1+) (E), AIRE+ mTEChi (CD45−MHC-IIhighLy51− AIRE+) (F). (G-J) Total TECs and individual TEC subsets were assessed for proliferation by continuous administration of BrdU in the drinking water (0.8 mg/mL) between day 10 and 14 after BMT at which point Total TECs (G), cTEC (H), mTEClo (I), and mTEChi subsets (J) were analyzed for BrdU incorporation. Data shown are the mean numbers of TEC (± SEM) or mean percentages of BrdU+ TEC (± SEM) and are representative of one experiment of 4 mice per group. *P < .05 compared with BMT control mice; #P < .05 compared with KGF- or leuprolide acetate-treated BMT recipients.

Combined pretreatment with KGF and androgen blockade maximally restores numbers of totalTECsand mTEC subsets by day 26afterBMT. (A-F) Lethally irradiated B6 recipients of allogeneic (BALB/c) bone marrow were left untreated (BMT Control) or pretreated with KGF, leuprolide acetate, or KGF + leuprolide acetate and analyzed for absolute numbers of TEC and TEC subsets at day 26 after BMT. Single-cell suspensions were prepared from enzymatic digests of individual thymi and used to determine total thymic epithelial cells (TEC; CD45MHC-II+) (A), cortical TEC (cTEC; CD45MHC-II+Ly51+) (B), medullary TEC (mTEC; CD45MHC-II+Ly51) (C), UEA-1+ mTEClo (CD45MHC-IIlowLy51 UEA-1+) (D), UEA-1+ mTEChi (CD45MHC-IIhighLy51 UEA-1+) (E), AIRE+ mTEChi (CD45MHC-IIhighLy51 AIRE+) (F). (G-J) Total TECs and individual TEC subsets were assessed for proliferation by continuous administration of BrdU in the drinking water (0.8 mg/mL) between day 10 and 14 after BMT at which point Total TECs (G), cTEC (H), mTEClo (I), and mTEChi subsets (J) were analyzed for BrdU incorporation. Data shown are the mean numbers of TEC (± SEM) or mean percentages of BrdU+ TEC (± SEM) and are representative of one experiment of 4 mice per group. *P < .05 compared with BMT control mice; #P < .05 compared with KGF- or leuprolide acetate-treated BMT recipients.

Close Modal

or Create an Account

Close Modal
Close Modal